AMD disclosed a $6.5 million stake in Marvell Technology through its latest 13F filing, with the position showing an estimated unrealized gain of approximately $4.3 million as Marvell shares have risen about 66% from AMD's implied entry price. The investment reflects AMD's exposure to AI infrastructure and data center semiconductor opportunities. AMD also holds positions in Absci Corp, Sanmina Corp, and Xanadu Quantum Technologies.

Absci Corporation granted 276,200 non-statutory stock options to a newly-hired non-executive employee on May 1, 2026, as an inducement for employment. The options have an exercise price of $4.92 per share with a 10-year term and vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal monthly installments over the following three years.

Absci Corporation announced the appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer to lead clinical development of its AI-designed therapeutics pipeline. Dr. Somaratne joins from Vertex Pharmaceuticals with extensive experience in clinical development. Chief Innovation Officer Andreas Busch will retire on March 31, 2026 and transition to co-chair the Scientific Advisory Board.

Absci, a clinical-stage biotech company using generative AI for drug discovery, will report its Q3 2025 financial and operating results on November 12, 2025, via a webcast conference call.

Absci Corporation announced participation in upcoming healthcare investor conferences and plans to host a key opinion leader (KOL) seminar on its ABS-201 hair regrowth program, with an accelerated Phase 1/2a trial expected to begin in December 2025.

Absci Corp, a small AI biotech company, offers high-risk investment potential in drug discovery using generative AI, with multiple drug candidates in clinical trials and strategic partnerships with major pharma companies.

The global CADD market is experiencing rapid growth, projected to generate substantial revenue between 2025-2034, driven by technological innovations, AI integration, and increasing demand across pharmaceutical and research sectors.

Absci partnered with Oracle Cloud Infrastructure and AMD to accelerate AI-driven drug discovery, leveraging high-performance computing infrastructure for molecular simulations and antibody design.

Absci Corporation announced participation in upcoming healthcare investor conferences and highlighted its AI-driven drug discovery platform, focusing on innovative therapeutics like ABS-101 for inflammatory bowel disease and ABS-201 for hair regrowth.

The antibody discovery market is projected to grow at a 10% CAGR by 2032, driven by increasing chronic disease incidence, biologics adoption, and technological advancements in drug development.

Absci Corporation announced a public offering of 16,670,000 shares of common stock at $3.00 per share, expecting to raise approximately $50 million to fund drug development programs and corporate purposes.

Absci Corporation plans to raise approximately $50 million through a public offering of 16,670,000 shares at $3.00 per share, with underwriters having an option to purchase additional shares. The proceeds will fund drug development programs and corporate initiatives.